This look ahead at hematologic malignancies in 2017 focuses on new agents being studied for the treatment of multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloproliferative neoplasms.
David Snyder, MD
Advertisement
Articles by David Snyder, MD
Advertisement
Latest Updated Articles
- Outlook for 2017: Myeloma, Lymphoma, and MPNs
Published: December 24th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Front-Line HNSCC
2
Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer
3
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
4
Safety Strategies for GPRC5D-Directed and T-Cell Engager Therapies
5
